Hunan Cancer Hospital
🇨🇳China
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT04922450
- Locations
- 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China
Research on Optimization and Evaluation of Oral Cancer Screening Methods
Early Phase 1
- Conditions
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 10000
- Registration Number
- NCT04919460
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04826406
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT04767295
- Locations
- 🇨🇳
Wenxiang Wang, Changsha, Hunan, China
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04459078
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT04414969
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT04407988
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 338
- Registration Number
- NCT04337632
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04239443
- Locations
- 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT03994744
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
© Copyright 2024. All Rights Reserved by MedPath